Home
Products
Learn
About
Pricing
Log In
Back
RHY
Asset Logo

Rhythm Biosciences Limited

πŸ‡¦πŸ‡Ί ASX

🩺 HEALTH CARE

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

-4.10%
Annual Growth

5 years average annual capital growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

11
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Rhythm Biosciences Ltd. engages in the research, development, and commercialization of medical diagnostics technologies. The firm is engaged in delivering simple, affordable blood tests for accurate and early detection of cancers. The company is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives. The firm has developed ColoSTAT, a blood test for the detection of Colorectal Cancer (CRC). The ColoSTAT Test-Kit measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. The company is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards. The firm also offers population level predictive risk testing for a range of cancers and other serious and common diseases.

πŸ“ˆ Performance

Price History

-67.41%

1M

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.07

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in RHY

11

πŸ“Š Total Capital Earnings

$19K

πŸ”ƒ Average investment frequency

26 weeks

πŸ’΅ Average investment amount

$1,493

⏰ Last time a customer invested in RHY

65 days
RHY investor breakdown
πŸ’΅ Income of investors

More than 200k

7%

150k - 200k

21%

100k - 150k

29%

50k - 100k

21%

Less than 50k

21%
πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

91%
πŸ™‹ Legal gender of investors

Female

45%

Male

55%

Pearlers who invest in RHY also invest in...

Rhythm Biosciences Limited

RHYN

Find Out More

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

πŸ™Œ Performance (5Yr p.a)

20.04%

πŸ“Š Share price

$49.75 AUD

πŸ‡ΊπŸ‡Έ UNITED STATES

πŸ“ˆ HIGH PRICE GROWTH

πŸ€– TECHNOLOGY

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

8.01%

πŸ“Š Share price

$105.93 AUD

πŸ‡¦πŸ‡Ί AUSTRALIA

🧱 MATERIALS

πŸ’Έ FINANCIALS

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

15.66%

πŸ“Š Share price

$139.54 AUD

🌏 GLOBAL

πŸ€– TECHNOLOGY

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

Pilbara Minerals Ltd. engages in the provision of exploration and evaluation of mineral properties. The company is headquartered in Perth, Western Australia and currently employs 917 full-time employees. The company went IPO on 2007-09-19. The firm owns 100% of an independent hard-rock lithium operation, the Pilgangoora operation in Australia, and the Colina Project in Brazil. Its Pilgangoora operation is located 140 kilometers (kms) from Port Hedland in Western Australia’s resource rich Pilbara region on Nyamal and Kariyarra Country. Spodumene concentrate from its Pilgangoora operation is shipped from Port Hedland, the bulk export port, to lithium chemical converters primarily in China. The firm's Colina project is located 10 kms from the town of Salinas in the world class mining jurisdiction of Minas Gerais, Brazil. The firm is also integrated into the lithium value chain through its joint venture with POSCO in South Korea, which manufactures battery-grade lithium hydroxide.

πŸ™Œ Performance (5Yr p.a)

84.91%

πŸ“Š Share price

$1.29 AUD

πŸ•ŠοΈ SOCIALLY AWARE

⛏️ MINING

Want more shares? Try these...

Resonance Health Ltd. operates as a healthcare company, which involves in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality controlled environment. The company is headquartered in Perth, Western Australia. Its portfolio includes Core Lab and artificial intelligence (AI)-powered products to partner with clinicians and radiologists for diagnosis, and management of patients. Its core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. Its other SaMDs include Cardiac T2, for the assessment of iron in the heart, and HepaFat-Scan for the assessment of fat in and around the liver. The company also has several AI-assisted SaMDs, including FerriSmart, HepaFat-AI, and LiverSmart. The company operates as the Clinical Trial Research Organisation (CRO) and local sponsor for a major global pharma company's clinical trial in Australia of a new drug compound.

πŸ™Œ Performance (5Yr p.a)

-15.53%

πŸ“Š Share price

$0.04 AUD

🩺 HEALTH CARE

Compare
Add to watchlist